Spironolactone in cardiovascular disease: an expanding universe? [version 1; referees: 2 approved]
Spironolactone has been marketed for over half a century as a ‘potassium-sparing diuretic’, used primarily in patients with ascites. With the realization that primary aldosteronism is the most common (5-13%) form of secondary hypertension, it has become widely used as a mineralocorticoid receptor an...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
F1000 Research Ltd
2017-09-01
|
| coleção: | F1000Research |
| Assuntos: | |
| Acesso em linha: | https://f1000research.com/articles/6-1738/v1 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|